Status:
COMPLETED
Role of Antimicrobial Peptides in Host Defense Against Vaccinia Virus
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
Atopic Dermatitis
Eligibility:
All Genders
2+ years
Brief Summary
Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by recurrent viral skin infections. Recent studies have demonstrated that the skin of people with AD my have decreased anti...
Detailed Description
AD is a chronic inflammatory skin disease characterized by frequent viral skin infections. Recent studies have found that components in the skin of people with AD may block AMP expression. AMPs are re...
Eligibility Criteria
Inclusion
- Inclusion Criteria for Participants With AD:
- 2 years of age or older
- History of active or inactive AD OR eczema herpeticum, as defined by the ADVN standardized diagnostic criteria
- Parent or guardian willing to provide informed consent, if applicable
- Male or female of any race and ethnicity
- Inclusion Criteria for Participants With Asthma or Psoriasis, and for non-atopic controls:
- 18 years or older
- History of psoriasis OR history of asthma not requiring systemic medications
- Parent or guardian willing to provide informed consent, if applicable
- Male or female of any race and ethnicity
- Exclusion Criteria:
- Oral corticosteroids or any systemic immunosuppressive or immunomodulatory medication within 28 days prior to study entry
- Immunotherapy within 3 months prior to study entry
- History of bleeding disorder
- Aspirin, oral antihistamines, oral antibiotics, oral cyclosporine, or topical medications within 7 days of screening visit including, but not restricted to, Protopic, Elidel, topical corticosteroids, and topical antibiotics
- Anxiolytic agents and antidepressants within 2 days of screening visit
- Diabetic requiring medication
- Autoimmune or immunodeficiency
- Active fungal, bacterial, or viral infections within 7 days prior to study entry
- Active systemic cancer. Participants with uncomplicated nonmelanoma skin cancer are not excluded.
- Theophylline or leukotriene antagonists within 24 hours of screening visit
- Received any vaccination within 30 days prior to study entry
- Known lidocaine allergy
- Previously vaccinated for smallpox
- Pregnant or breastfeeding
Exclusion
Key Trial Info
Start Date :
June 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2010
Estimated Enrollment :
286 Patients enrolled
Trial Details
Trial ID
NCT00407069
Start Date
June 1 2005
End Date
February 1 2010
Last Update
October 18 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Jewish Health
Denver, Colorado, United States, 80207